Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate From Other Disease-Modifying Therapies
Authors: Denise Bruen, MSN; Meghan Garabedian, CRNP, MSN, MSCN; Cortnee Roman, MSN, FNP-BC; Nicholas W. Robinson, MA; Meg M. Stabb, MBA; Virginia R. Schobel, MSc; Jason P. Mendoza, Ph.D.; James B. Lewin, PharmD; Mary Zhang, PharmD; Sai L. Shankar, Ph.D. BACKGROUND: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by […]
Therapy Selection Considerations During the COVID-19 Pandemic Among Patients With Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit
Authors: Virginia R. Schobel, MSc; Meg M. Stabb BACKGROUND: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of multiple sclerosis (MS). OBJECTIVE: To assess the impact of COVID-19-related concerns on disease-modifying therapy (DMT) selection patterns for progressive MS. METHODS: In July-August 2020, US […]
Aduhelm Administration Remains a Trickle, ARIA a Concern
From: Alzforum By: Madolyn Bowman Rogers While three other Alzheimer’s immunotherapies are barreling down the approval pike, the first one to have nabbed a marketing license continues to tread an uncertain path. Several hospital systems have chosen not to provide the drug, and some insurers refuse to cover its cost. Thus far, only a […]
Bristol Myers Squibb’s Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen’s Ponvory Could Likewise Stumble
If reimbursement hurdles can be overcome, Zeposia may be well positioned for more favorable early line use and less within-S1P class competition in the UK versus in Germany EXTON, Pa., October 20, 2021 /PRNewswire/ — Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb’s Zeposia and the May 2021 approval of Janssen’s Ponvory, […]
Launching a Drug in the Era of COVID-19: How Important is Sales Representative Contact Really?
By: Eric John Pandemic aside (if you can imagine that), launching a drug in the pharmaceutical industry is no walk in the park. There are a number of factors that influence the success (or failure) of a new brand, including clinical performance (efficacy, tolerability, safety, etc.), insurance coverage/cost, and manufacturer perceptions – just to name […]
Amgen’s Aimovig and Eli Lilly’s Emgality Feel the Heat From Strong Uptake of Biohaven’s Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights
New research suggests that Amgen’s and Eli Lilly’s increased promotional efforts towards PCPs will be vital to minimizing the future impact of Nurtec ODT and AbbVie’s recently approved Qulipta EXTON, Pa., October 12, 2021 /PRNewswire/ — Following the May 2021 FDA approval of Biohaven’s Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs) […]
Post-Launch Insights Point to Four Key Factors That Could Drive Future Use of Biogen/Eisai’s Aduhelm in Alzheimer’s Disease
What the Aduhelm manufacturers and others with agents in the pipeline can learn from early launch metrics EXTON, Pa., October 7, 2021 /PRNewswire/ — At three months post-launch, the high expectations for Biogen/Eisai’s Aduhelm in Alzheimer’s disease have not quite materialized. Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever […]
Systemic Lupus Erythematosus Patients With and without Renal Involvement: A Real World Analysis Showing Demographics, Clinical and Treatment Differences Across More Than 1,000 Patients
Authors: Maxine Yarnall, Tucker Hurtado, Vibeke Strand BACKGROUND and AIMS: present significant challenges in management. This study was to evaluate moderate to severely active SLE patients and determine overlapping characteristics and significant differences among this cohort of SLE patients with and without renal involvement. METHODS: 1,010 SLE patient records were collected in collaboration with […]
Evolving Mechanism of Action Preference for the Treatment of Psoriatic Arthritis in the US and EU5
Authors: Maxine Yarnall BACKGROUND and AIMS: Treatment for psoriatic arthritis (PsA) is largely accounted for by TNFs and their respective biosimilars. However, the introduction of alternate MOAs (AMOAs) has resulted in shifting preferences, with many rheumatologists expecting a greater role for new agents, albeit this dynamic varies by country. METHODS: An independent market analytics […]
Comparison of Rheumatoid Arthritis Patients Recently Switched to JAK Inhibitor Therapy in the US and EU5: Comorbidity and Switch Pattern Analysis from Patient Chart Audit
Authors: Maxine Yarnall, Chrystal Ferguson BACKGROUND and AIMS: As use of Januse Kinase Inhibitor (JAKi) therapies in rheumatoid arthritis (RA) have increased, so has awareness of cardiovascular (CV) and malignancy safety concerns associated with the class. This study’s goal is to compare gender, comorbidities and JAKi use in RA patients switched to JAKi therapies […]
